New clinical research has demonstrated that the prebiotic Bimuno, a unique trans-galactooligosaccharide, has the ability to reduce anxiety. Clasado Biosciences Limited, the producers and suppliers of Bimuno, in conjunction with the Department of Psychiatry, University of Oxford, announced the results of the clinical trial, which was published in the journal Psychopharmacology in a paper entitled ‘Prebiotic intake reduces the waking cortisol response and alters emotional bias in healthy volunteers.”
 
Results showed that the consumption of B-GOS produced a decrease in both waking cortisol levels and attentional vigilance towards negative versus positive information. The trial compared B-GOS with fructooligosaccharide (FOS) and a placebo. 
 
The study’s conclusion suggests that B-GOS may have an anxiolytic effect and reduce stress reactivity in healthy subjects. The study also demonstrates that manipulation of the gut microbiota with B-GOS may alter HPA (hypothalamic-pituitary-adrenal) axis reactivity and processing. The HPA axis is often dysregulated in individuals suffering from depression and anxiety impacting affective and memory processing as well as having strong directional links with the gut microbiome.
 
The study revealed decreased attentional vigilance to negative versus positive information after Bimuno GOS treatment, compared to placebo and FOS treatment. Increased processing of negative material is seen as a core functional marker of anxiety and depression and can be modulated by antidepressant/anxiolytic medication. No effects were found after administration of a FOS prebiotic.
 
Further trials are planned by Clasado and the University of Oxford studying the effects of B-GOS on individuals suffering from anxiety, stress or depression.
 
The clinical study is the latest in an ongoing research program of pre-clinical and clinical trials being undertaken by Clasado in collaboration with Oxford University and other internationally recognized research institutes. This study followed a recent pre-clinical trial, published in the journal Neurochemistry International, which showed for the first time that the modulation of gut microbiota by prebiotics can lead to changes in brain biochemistry. 
 
“Mental health problems affect a significant proportion of people in the western world. Indeed, depression and anxiety account for 40% of reported disabilities worldwide. This latest study by Clasado and the Department of Psychiatry, University of Oxford is a valuable addition to our knowledge of brain gut interactions and may pave the way for alternatives to existing drug therapies with their associated side effects,” said Graham Waters, CEO of Clasado. “This trial is part of a wider program of clinical research in which we are currently engaged, investigating the central role of the gut in improved health and wellness.”
 
Twenty five percent of people in the western world will experience a mental health problem at some point during a 12 month period and anxiety is the most common mental illness, affecting approximately one in six people in the U.S. and U.K.
 
“The results of these trials add to the expanding body of knowledge on microbiome-behaviour and microbiome-endocrine interactions,” said Dr. Phil Burnet, head researcher, Department of Psychiatry, University of Oxford. “The study makes an important contribution to the existing clinical evidence linking the gut and its microbiota to brain function.”
 
For more information: www.clasado.com